keyword
https://read.qxmd.com/read/37776107/determination-and-confirmation-of-recommended-ph2-dose-of-amivantamab-in-epidermal-growth-factor-receptor-exon-20-insertion-non-small-cell-lung-cancer
#1
JOURNAL ARTICLE
Nahor Haddish-Berhane, Yaming Su, Alberto Russu, Meena Thayu, Roland E Knoblauch, Jaydeep Mehta, John Xie, Eric Gibbs, Yu-Nien Sun, Honghui Zhou
Amivantamab has demonstrated durable responses with a tolerable safety profile in NSCLC with EGFR exon 20 insertions (Ex20ins) who progressed after prior platinum chemotherapy. Data supporting the amivantamab recommended phase 2 dose (RP2D) in this patient population are presented. Pharmacokinetic (PK) analysis and population PK (PopPK) modeling were conducted using serum concentration data obtained following amivantamab intravenous administration (140-1750 mg). Pharmacodynamics (PD) were evaluated using depletion of soluble EGFR and MET (mesenchymal-epithelial transition factor)...
September 30, 2023: Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/36077610/expression-of-sars-cov-2-related-surface-proteins-in-non-small-cell-lung-cancer-patients-and-the-influence-of-standard-of-care-therapy
#2
JOURNAL ARTICLE
Christophe Deben, Maxim Le Compte, Vasiliki Siozopoulou, Hilde Lambrechts, Christophe Hermans, Ho Wa Lau, Manon Huizing, Kevin Lamote, Jeroen M H Hendriks, Peter Van Dam, Patrick Pauwels, Evelien L J Smits, Marc Peeters, Filip Lardon
In this study, we aimed to study the expression of SARS-CoV-2-related surface proteins in non-small-cell lung cancer (NSCLC) cells and identify clinicopathological characteristics that are related to increased membranous (m)ACE2 protein expression and soluble (s)ACE2 levels, with a particular focus on standard of care (SOC) therapies. ACE2 ( n = 107), TMPRSS2, and FURIN ( n = 38) protein expression was determined by immunohistochemical (IHC) analysis in NSCLC patients. sACE2 levels ( n = 64) were determined in the serum of lung cancer patients collected before, during, or after treatment with SOC therapies...
August 23, 2022: Cancers
https://read.qxmd.com/read/35970411/ledgf-is-a-new-growth-factor-in-fetal-serum
#3
JOURNAL ARTICLE
Zhuo Zhen Chen, Peter Bowden, Jaimie Dufresne, Ming Miao, John G Marshall
Fetal serum supports the immortal growth of mammalian cell lines in culture while adult serum leads to the terminal differentiation and death of cells in culture. Many of the proteins in fetal serum that support the indefinite division and growth of cancerous cell lines remain obscure. The peptides and proteins of fetal versus adult serum were analyzed by liquid chromatography, nano electrospray ionization and tandem mass spectrometry (LC-ESI-MS/MS). Three batches of fetal serum contained the Alpha Fetoprotein marker while adult serum batches did not...
August 12, 2022: Analytical Biochemistry
https://read.qxmd.com/read/35822688/prognostic-value-of-soluble-programmed-cell-death-ligand-1-in-patients-with-non-small-cell-lung-cancer-a-meta-analysis
#4
REVIEW
Yan Wang, Haiyun He
Background: Previously published data was collected and a meta-analysis was conducted to precisely identify the prognostic and clinicopathological significance of soluble programmed cell death ligand-1 (sPD-L1) in patients with non-small-cell lung cancer (NSCLC). Materials & methods: Combined hazard ratios (HRs), odds ratios and 95% confidence intervals were used to assess the correlation between sPD-L1 expression and prognosis in patients with NSCLC. Results: A total of 11 studies with 976 patients were included in this meta-analysis...
August 2022: Immunotherapy
https://read.qxmd.com/read/35582197/low-expression-of-mir-27b-in-serum-exosomes-of-non-small-cell-lung-cancer-facilitates-its-progression-by-affecting-egfr
#5
JOURNAL ARTICLE
Xiying Cao, Weixiang Zhong, Shaoming Guo, Zuxiong Zhang, Chunfa Xie
Non-small cell lung cancer (NSCLC) is a malignant tumor. Serum exosomal miR-27b is related to tumor diagnosis. We explored the roles of serum exosomal miR-27b in NSCLC. NSCLC patients were assigned to NSCLC-early/terminal groups, with healthy subjects as controls. miR-27b expression was assessed using reverse transcription-quantitative polymerase chain reaction, and its diagnostic efficiency was analyzed using the receiver operating characteristic curve. The correlation between serum exosomal miR-27b expression and tumor markers carcinoembryonic antigen 125 (CA125), carcinoembryonic antigen (CEA), and cytokeratin 19-soluble fragment (CYFRA21-1) was analyzed using the Pearson analysis...
2022: Open Medicine (Warsaw, Poland)
https://read.qxmd.com/read/35543090/dynamic-monitoring-serum-tumor-markers-to-predict-molecular-features-of-egfr-mutated-lung-cancer-during-targeted-therapy
#6
JOURNAL ARTICLE
Zhuxing Chen, Liping Liu, Feng Zhu, Xiuyu Cai, Yi Zhao, Peng Liang, Limin Ou, Ran Zhong, Ziwen Yu, Caichen Li, Jianfu Li, Shan Xiong, Yi Feng, Bo Cheng, Hengrui Liang, Zhanhong Xie, Wenhua Liang, Jianxing He
To reveal the correlation of dynamic serum tumor markers (STMs) and molecular features of epidermal growth factor receptor-mutated (EGFR-mutated) lung cancer during targeted therapy, we retrospectively reviewed 303 lung cancer patients who underwent dynamic STM tests [neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153), the soluble fragment of cytokeratin 19 (CYFRA21-1), and squamous cell carcinoma antigen (SCC)] and circulating tumor DNA (ctDNA) testing with a panel covering 168 genes...
August 2022: Cancer Medicine
https://read.qxmd.com/read/35397434/safety-and-preliminary-activity-results-of-the-gatto-study-a-phase-ib-study-combining-the-anti-ta-muc1-antibody-gatipotuzumab-with-the-anti-egfr-tomuzotuximab-in-patients-with-refractory-solid-tumors
#7
JOURNAL ARTICLE
S Ochsenreither, W M Fiedler, G D Conte, M Macchini, I Matos, B Habel, I Ahrens-Fath, F Raspagliesi, D Lorusso, U Keilholz, C Rolling, M Kebenko, K F Klinghammer, O Saavedra, H Baumeister, A Zurlo, E Garralda
BACKGROUND: The phase I GATTO study (NCT03360734) explored the feasibility, tolerability and preliminary activity of combining gatipotuzumab, a novel humanized monoclonal antibody binding to the tumor-associated epitope of mucin 1 (TA-MUC1) and an anti-epidermal growth factor receptor (anti-EGFR) antibody in refractory solid tumors. PATIENTS AND METHODS: Initially the study enrolled primary phase (PP) patients with EGFR-positive metastatic solid tumors, for whom no standard treatment was available...
April 2022: ESMO Open
https://read.qxmd.com/read/33462734/correlations-between-serum-cetuximab-and-egfr-related-markers-and-skin-disorders-in-head-and-neck-cancer-patients
#8
JOURNAL ARTICLE
Kaito Shibata, Takafumi Naito, Satoshi Hirakawa, Koji Suzuki, Seiji Hosokawa, Hiroyuki Mineta, Junichi Kawakami
PURPOSE: Cetuximab inhibits epidermal growth factor receptor (EGFR) signaling in cancer and skin cells, thereby inducing anti-cancer effects and skin disorders. The present study aimed to evaluate the relationships between serum cetuximab and EGFR-related markers, and adverse effects in head and neck cancer patients. METHODS: Thirty-four head and neck cancer patients receiving weekly intravenous cetuximab were enrolled. Serum cetuximab levels were determined just before dosing...
April 2021: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/32156745/integrative-omics-analysis-reveals-soluble-cadherin-3-as-a-survival-predictor-and-an-early-monitoring-marker-of-egfr-tyrosine-kinase-inhibitor-therapy-in-lung-cancer
#9
JOURNAL ARTICLE
Ting-Feng Hsiao, Chih-Liang Wang, Yi-Cheng Wu, Hsiang-Pu Feng, Yen-Chuan Chiu, Hao-Yu Lin, Ko-Jiunn Liu, Gee-Chen Chang, Kun-Yi Chien, Jau-Song Yu, Chia-Jung Yu
PURPOSE: EGFR tyrosine kinase inhibitors (EGFR-TKI) benefit patients with advanced lung adenocarcinoma (ADC) harboring activating EGFR mutations. We aimed to identify biomarkers to monitor and predict the progression of patients receiving EGFR-TKIs via a comprehensive omic analysis. EXPERIMENTAL DESIGN: We applied quantitative proteomics to generate the TKI resistance-associated pleural effusion (PE) proteome from patients with ADC with or without EGFR-TKI resistance...
July 1, 2020: Clinical Cancer Research
https://read.qxmd.com/read/31707279/value-of-serum-tumor-markers-for-predicting-egfr-mutations-and-positive-alk-expression-in-1089-chinese-non-small-cell-lung-cancer-patients-a-retrospective-analysis
#10
JOURNAL ARTICLE
Sufei Wang, Pei Ma, Guanzhou Ma, Zhilei Lv, Feng Wu, Mengfei Guo, Yumei Li, Qi Tan, Siwei Song, E Zhou, Wei Geng, Yanran Duan, Yan Li, Yang Jin
PURPOSE: The role of serum tumor markers (STMs) in the modern management of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations in lung cancer remains poorly described. In this study, we investigated whether STMs could be a valuable noninvasive tool to predict EGFR mutations and ALK positivity in non-small-cell lung cancer (NSCLC) patients. EXPERIMENTAL DESIGN: We retrospectively reviewed and included 1089 NSCLC patients who underwent EGFR or ALK mutation testing and STMs measurement prior to treatment...
January 2020: European Journal of Cancer
https://read.qxmd.com/read/31346234/serum-slyve-1-is-not-associated-with-coronary-disease-but-with-renal-dysfunction-a-retrospective-study
#11
JOURNAL ARTICLE
Daopeng Dai, Chunkai Huang, Jinwei Ni, Zhenbin Zhu, Hui Han, Jinzhou Zhu, Ruiyan Zhang
Recent evidence has indicated that the lymphatic vessel endothelial hyaluronan receptor (LYVE-1) is implicated in chronic inflammation and the lymphatic immune response. The soluble form of LYVE-1 (sLYVE-1) is produced by ectodomain shedding of LYVE-1 under pathological conditions including cancer and chronic inflammation. In this study, 1014 consecutive patients who underwent coronary angiography from May 2015 to September 2015 were included to investigate whether serum sLYVE-1 is associated with coronary artery disease (CAD) and its concomitant diseases includes chronic kidney disease (CKD)...
July 25, 2019: Scientific Reports
https://read.qxmd.com/read/31012144/synthesis-of-novel-gefitinib-based-derivatives-and-their-anticancer-activity
#12
JOURNAL ARTICLE
Mrunal J Sharma, Maushmi S Kumar, Manikanta Murahari, Y C Mayur
Drug latentiation is a process of modifying a drug molecule structurally to improve its binding affinity as well as increasing the drug-receptor interactions and potentiate its therapeutic potential. In the quest for discovering more potent epidermal growth factor receptor (EGFR) inhibitors, gefitinib-based derivatives were designed by simple structural modification at the secondary amine of gefitinib by N-alkylation. Three gefitinib derivatives (gefitinib-NB, -NP, and -NIP) were synthesized by N-alkylation and phase transfer catalysis...
May 2019: Archiv der Pharmazie
https://read.qxmd.com/read/30302966/soluble-dipeptidyl-peptidase-4-levels-are-associated-with-decreased-renal-function-in-patients-with-type-2-diabetes-mellitus
#13
JOURNAL ARTICLE
Eun Hee Cho, Sang Wook Kim
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) is strongly expressed in the kidney, and soluble levels of this protein are used as a marker in various chronic inflammatory diseases, including diabetes, coronary artery disease, and cancer. This study examined the association between the serum soluble DPP-4 levels and renal function or cardiovascular risk in patients with type 2 diabetes mellitus. METHODS: In this retrospective analysis, soluble DPP-4 levels were measured in preserved sera from 140 patients with type 2 diabetes mellitus who had participated in our previous coronary artery calcium (CAC) score study...
February 2019: Diabetes & Metabolism Journal
https://read.qxmd.com/read/30039310/exploring-pitfalls-of-64-cu-labeled-egfr-targeting-peptide-ge11-as-a-potential-pet-tracer
#14
JOURNAL ARTICLE
Franziska Striese, Wiebke Sihver, Feng Gao, Ralf Bergmann, Martin Walther, Jens Pietzsch, Jörg Steinbach, Hans-Jürgen Pietzsch
The epidermal growth factor receptor (EGFR) represents an important molecular target for both radiotracer-based diagnostic imaging and radionuclide therapy of various cancer entities. For the delivery of radionuclides to the tumor, peptides hold great potential as a transport vehicle. With respect to EGFR, the peptide YHWYGYTPQNVI (GE11) has been reported to bind the receptor with high specificity and affinity. In the present study, GE11 with β-alanine (β-Ala-GE11) was conjugated to the chelating agent p-SCN-Bn-NOTA and radiolabeled with 64 Cu for the first radio pharmacological evaluation as a potential probe for positron emission tomography (PET)-based cancer imaging...
October 2018: Amino Acids
https://read.qxmd.com/read/29908185/design-and-development-of-pegylated-liposomal-formulation-of-her2-blocker-lapatinib-for-enhanced-anticancer-activity-and-diminished-cardiotoxicity
#15
JOURNAL ARTICLE
Richa Shrivastava, Shruti Trivedi, Pankaj Kumar Singh, Mohammad Asif, Manish Kumar Chourasia, Amit Khanna, Smrati Bhadauria
Breast cancer is most frequently diagnosed cancer and fifth leading cause of death in women. About 20-30% of all breast cancers overexpress HER2/neu receptors. Lapatinib is a dual tyrosin kinase inhibitor of EGFR and HER2. It exhibits its anticancer effect via blocking intracellular domain of HER2 receptor in breast cancer. Lapatinib belongs to class II of BSC classification due to its poor solubility restricting its clinical application. Due to presence of HER2 receptor on cardiomyocytes, it is associated with generation of cardiotoxicity...
September 5, 2018: Biochemical and Biophysical Research Communications
https://read.qxmd.com/read/28923567/a-water-soluble-polysaccharide-from-the-roots-of-polygala-tenuifolia-suppresses-ovarian-tumor-growth-and-angiogenesis-in-vivo
#16
JOURNAL ARTICLE
Hua Yao, Ping Cui, Dan Xu, Yunduo Liu, Qinghua Tian, Fubin Zhang
PTP, one polysaccharide extracted from the roots of Polygala tenuifolia, has displayed anti-cancer activity in several types of ovarian cancer cells. This study aims to elucidate the structure of PTP and investigate its anticancer effects against SKOV3 xenograft tumor growth in BALB/c mice, as well as the underlying mechanisms involved. GC-MS and NMR data indicate that PTP has a backbone composed of 1,4,6-linked-β-Galp, 1,4-linked-β-Galp and 1,4-linked-β-Glcp, with non-reducing terminal 1-linked-α-Glcp attached to O-6 of 1,4,6-linked-β-Galp...
February 2018: International Journal of Biological Macromolecules
https://read.qxmd.com/read/28101024/bazex-syndrome-in-lung-squamous-cell-carcinoma-high-expression-of-epidermal-growth-factor-receptor-in-lesional-keratinocytes-with-th2-immune-shift
#17
Maki Amano, Takaaki Hanafusa, Sakiko Chikazawa, Makiko Ueno, Takeshi Namiki, Ken Igawa, Keiko Miura, Hiroo Yokozeki
An 82-year-old Japanese man was referred for detailed examination of hyperkeratotic erythematous plaques on his palms and soles for 6 months. Two weeks before his first visit, he had undergone lung lobectomy for right lung squamous cell carcinoma (SCC). Laboratory findings showed elevations of eosinophil counts, serum IgE, thymus and activation-regulated chemokine, SCC antigen, and soluble interleukin-2 receptor levels. Histological results of a skin biopsy involving the left palm showed psoriasiform dermatitis...
September 2016: Case Reports in Dermatology
https://read.qxmd.com/read/28057155/-level-of-soluble-programmed-death-1-ligand-1-in-peripheral-blood-of-patients-with-advanced-epidermal-growth-factor-receptor-mutated-lung-adenocarcinoma-and-its-clinical-implications
#18
JOURNAL ARTICLE
L Q Zhang, Y Chen, X Pan, Y F Xing, M H Shi, Y J Chen
Objective: To analyze the expression of soluble programmed death ligand 1 (sPD-L1) in the serum of patients with advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma and to explore its clinical implications. Methods: Seventy-two patients with EGFR mutated advanced lung adenocarcinoma (EGFR mutation group) were included from the Department of Respiratory Diseases in The Second Affiliated Hospital of Soochow University from May 2015 to July 2016. Thirty-one patients with advanced EGFR wild type (WT) lung adenocarcinoma [EGFR WT group, diagnosed via mini specimens from bronchoscopy or transthoracic needle aspiration biopsy (TNAB), matching in sex, age and tumor stage with EGFR mutation group] were also enrolled as controls...
December 27, 2016: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://read.qxmd.com/read/27666533/an-evaluation-of-multiplex-bead-based-analysis-of-cytokines-and-soluble-proteins-in-archived-lithium-heparin-plasma-edta-plasma-and-serum-samples
#19
JOURNAL ARTICLE
Line Brøndum, Brita Singers Sørensen, Jesper Grau Eriksen, Lise Saksø Mortensen, Simon Lønbro, Jens Overgaard, Jan Alsner
OBJECTIVE: To assess the usability of archived plasma and serum by multiplex (Luminex) analysis of circulating proteins (analytes) by evaluating the day to day variation, the effect of several freeze-thaw cycles, and the influence of the media and choice of anticoagulant. METHODS: Nineteen analytes in plasma and serum from 86 head and neck cancer patients and 33 controls were evaluated: EGFR, leptin, OPN, VEGFR-1, VEGFR-2, IL-2, IL-13, PDGF-bb, TNF, PAI-1, SDF-1a, IL-4, IL-6, IL-8, eotaxin, G-CSF, VEGF, GRO-a, and HGF...
December 2016: Scandinavian Journal of Clinical and Laboratory Investigation
https://read.qxmd.com/read/27597284/increase-in-soluble-pd-1-is-associated-with-prolonged-survival-in-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer-treated-with-erlotinib
#20
COMPARATIVE STUDY
Steffen Filskov Sorensen, Christina Demuth, Britta Weber, Boe Sandahl Sorensen, Peter Meldgaard
OBJECTIVES: The central immune co-inhibitory programmed cell death receptor/ligand 1 (PD-1/PD-L1) pathway plays a key role in tumor immune evasion in non-small cell lung cancer (NSCLC). Soluble PD-1 (sPD-1) can be detected in the blood, and preclinical evidence suggests that sPD-1 blocks PD-1/-L1 interaction and improves anti-tumor immunity. The present study compares the concentration of sPD-1 in the serum of advanced NSCLC patients with Epidermal Growth Factor Receptor (EGFR) mutation prior to erlotinib treatment and at the time of progression and correlates these results to patient outcome...
October 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
keyword
keyword
104692
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.